Dilution is always bad for current investors. It decreases the value of each share they own. Yes , you are correct in saying its almost mandatory in the biotech sector but by no means does it imply it's a good thing. Raising capital at the lowest dilution rates is the key. When this is accomplished it minimizes the damage to current investors. Leo is doing just the opposite...
News 
Market Data 
Discover 
